Patient approach in advanced/metastatic renal cell carcinoma: Focus on the elderly population and treatment-related toxicity

Elena Verzoni, Filippo De Braud, Francesca Fabiani, Paolo Grassi, Isabella Testa, Giuseppe Procopio

Research output: Contribution to journalArticlepeer-review

Abstract

Recent therapeutic advances have changed the treatment landscape of metastatic renal cell carcinoma. Unfortunately, the seven agents now available are not based on biomarkers that would indicate which one could provide the best benefit for every patient. We have reviewed the available information concerning the impact of each treatment on comorbidities or status that are frequently seen before commencing treatment for the advanced disease: elderly and patients with cardiovascular complications, metabolic and endocrinology disorders, and infections, as well as impaired organ function (kidney, liver and heart). Additional new drugs will be launched, but no predictive biomarkers are available. Head-to-head studies to evaluate the safety of the different drugs are rare. In this quite complex scenario, we believe that a decision-making approach focused on the patient may represent a suitable strategy.

Original languageEnglish
Pages (from-to)1599-1607
Number of pages9
JournalFuture Oncology
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2013

Keywords

  • elderly patient
  • metastatic renal cell carcinoma
  • sorafenib
  • sunitinib
  • targeted therapy
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Patient approach in advanced/metastatic renal cell carcinoma: Focus on the elderly population and treatment-related toxicity'. Together they form a unique fingerprint.

Cite this